{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T20:50:23Z","timestamp":1785790223740,"version":"3.56.0"},"reference-count":16,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"9","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,9]]},"abstract":"<jats:p>\n                    A 72-year-old man presented with severe weight loss, anemia, and a PSA level of 73\u00a0ng\/mL. Bone scintigraphy and\n                    <jats:sup>99m<\/jats:sup>\n                    Tc-PSMA imaging revealed extensive skeletal metastases. As part of a clinical trial, he received upfront\n                    <jats:sup>177<\/jats:sup>\n                    Lu-PSMA radioligand therapy combined with androgen-deprivation therapy (ADT). The second cycle of\n                    <jats:sup>177<\/jats:sup>\n                    Lu-PSMA resulted in complete resolution of all PSMA-avid lesions and a 99% decline in PSA to &lt;0.4\u00a0ng\/mL. Radioligand therapy was discontinued after achieving complete molecular and biochemical response. At 8 months of follow-up, the patient remains disease-controlled, supporting the potential value of early\n                    <jats:sup>177<\/jats:sup>\n                    Lu-PSMA integration in hormone-sensitive metastatic prostate cancer.\n                  <\/jats:p>","DOI":"10.1097\/rlu.0000000000006411","type":"journal-article","created":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T19:00:47Z","timestamp":1774638047000},"page":"e772-e774","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Upfront 177Lu-PSMA Radioligand Therapy With Concurrent Androgen-deprivation Therapy Producing Dramatic Clinical and Biochemical Response"],"prefix":"10.1097","volume":"51","author":[{"given":"Haniye","family":"Elahifard","sequence":"first","affiliation":[{"name":"Nuclear Medicine Research Center, Mashhad University of Medical Sciences"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amin","family":"Saber Tanha","sequence":"additional","affiliation":[{"name":"Nuclear Medicine Research Center, Mashhad University of Medical Sciences"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salman","family":"Soltani","sequence":"additional","affiliation":[{"name":"Department of Urology, Imam Reza Hospital, Mashhad University of Medical Sciences, Mashhad, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Shafiei","sequence":"additional","affiliation":[{"name":"Nuclear Medicine Research Center, Mashhad University of Medical Sciences"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atena","family":"Aghaee","sequence":"additional","affiliation":[{"name":"Nuclear Medicine Research Center, Mashhad University of Medical Sciences"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,3,10]]},"reference":[{"key":"R1-20260803","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1517\/14656566.9.2.211","article-title":"Androgen deprivation therapy for prostate cancer","volume":"9","author":"Singer","year":"2008","journal-title":"Expert Opin Pharmacother"},{"key":"R2-20260803","doi-asserted-by":"crossref","first-page":"e433126","DOI":"10.1200\/EDBK_433126","article-title":"Balancing hormone therapy: mitigating adverse effects of androgen-deprivation therapy and exploring alternatives in prostate cancer management","volume":"44","author":"Gudenkauf","year":"2024","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"R3-20260803","doi-asserted-by":"crossref","first-page":"1991","DOI":"10.3390\/cancers16111991","article-title":"Metabolic response to androgen deprivation therapy of prostate cancer","volume":"16","author":"Chen","year":"2024","journal-title":"Cancers (Basel)"},{"key":"R4-20260803","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1097\/RLU.0000000000005212","article-title":"Radionuclide therapy with 177Lu-PSMA in a patient with hepatocellular carcinoma","volume":"49","author":"Pretet","year":"2024","journal-title":"Clin Nucl Med"},{"key":"R5-20260803","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1097\/RLU.0000000000005583","article-title":"Outcome and renal safety of PSMA-targeted radioligand therapy in mCRPC patients with preexisting impaired renal function","volume":"50","author":"Bastian","year":"2025","journal-title":"Clin Nucl Med"},{"key":"R6-20260803","doi-asserted-by":"crossref","first-page":"e8","DOI":"10.1097\/RLU.0000000000004964","article-title":"Isolated adrenal metastases of castration-resistant prostate cancer","volume":"49","author":"Topal","year":"2024","journal-title":"Clin Nucl Med"},{"key":"R7-20260803","doi-asserted-by":"crossref","first-page":"e617","DOI":"10.1097\/RLU.0000000000005445","article-title":"Tumor lysis syndrome following PSMA radioligand therapy","volume":"49","author":"Sahafi","year":"2024","journal-title":"Clin Nucl Med"},{"key":"R8-20260803","doi-asserted-by":"crossref","first-page":"TPS210","DOI":"10.1200\/JCO.2022.40.6_suppl.TPS210","article-title":"PSMAddition: a phase 3 trial to compare treatment with 177 Lu-PSMA-617 plus standard of care (SOC) versus SOC alone in patients with metastatic hormone-sensitive prostate cancer","volume":"40","author":"Sartor","year":"2022","journal-title":"J Clin Oncol"},{"key":"R9-20260803","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1097\/RLU.0000000000004919","article-title":"PSMA radioligand therapy in prostate cancer","volume":"49","author":"Almeida","year":"2024","journal-title":"Clin Nucl Med"},{"key":"R10-20260803","doi-asserted-by":"crossref","first-page":"e248","DOI":"10.1097\/RLU.0000000000005624","article-title":"Superscan in first posttherapeutic 177Lu-PSMA scan","volume":"50","author":"Calderon Tobar","year":"2025","journal-title":"Clin Nucl Med"},{"key":"R11-20260803","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1097\/RLU.0000000000005222","article-title":"Favorable response of 225Ac-PSMA in the treatment of castration-resistant prostate cancer with high bone metastasis burden","volume":"49","author":"Wang","year":"2024","journal-title":"Clin Nucl Med"},{"key":"R12-20260803","doi-asserted-by":"crossref","first-page":"298-309","DOI":"10.1007\/s12149-025-02127-3","article-title":"Efficacy and safety of Lutetium-177 (177Lu)-PSMA-617 in metastatic castration-resistant prostate cancer patients with superscan pattern: a retrospective cohort study","volume":"40","author":"Shamshirgaran","year":"2026","journal-title":"Ann Nucl Med"},{"key":"R13-20260803","doi-asserted-by":"crossref","first-page":"e276","DOI":"10.1097\/RLU.0000000000005163","article-title":"Complete resolution of locally advanced prostate cancer after molecular endoradiotherapy with 177Lu-PSMA","volume":"49","author":"Beheshti","year":"2024","journal-title":"Clin Nucl Med"},{"key":"R14-20260803","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1097\/RLU.0000000000005010","article-title":"177Lu-PSMA-617 therapy in a case of metastatic castration-resistant prostate cancer","volume":"49","author":"Qu","year":"2024","journal-title":"Clin Nucl Med"},{"key":"R15-20260803","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1097\/RLU.0000000000005589","article-title":"Re-rechallenge 177Lu-PSMA-617 radioligand therapy in metastatic castration-resistant prostate cancer","volume":"50","author":"Aggarwal","year":"2025","journal-title":"Clin Nucl Med"},{"key":"R16-20260803","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1007\/s00259-024-06905-5","article-title":"Efficacy and safety of rechallenge with [177Lu]Lu-PSMA-I&T radioligand therapy in metastatic castration resistant prostate cancer","volume":"52","author":"Santo","year":"2024","journal-title":"Eur J Nucl Med Mol Imaging"}],"container-title":["Clinical Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/RLU.0000000000006411","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T20:01:49Z","timestamp":1785787309000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/RLU.0000000000006411"}},"subtitle":["A Case Report"],"short-title":[],"issued":{"date-parts":[[2026,3,10]]},"references-count":16,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/rlu.0000000000006411","relation":{},"ISSN":["0363-9762","1536-0229"],"issn-type":[{"value":"0363-9762","type":"print"},{"value":"1536-0229","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,10]]},"assertion":[{"value":"2025-12-01","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-02-08","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}